Q4 2022 Results
Company overview
Innovation: Pipeline overview
Cardiovascular
Financial review
Immunology
LeqvioⓇ - siRNA (regulation of LDL-C)
2023 priorities
Innovation: Clinical trials
Neuroscience
NCT05030428 VICTORION-2P (CKJX839B12302)
Indication
Phase
Patients
Primary
Outcome
Measures
Arms
Intervention
Secondary prevention of cardiovascular events in patients with elevated levels
of LDL-C
Phase 3
15000
1. Time to First Occurrence of 3P-MACE (3-Point Major Adverse
Cardiovascular Events)
Arm 1: Experimental Inclisiran sodium, Subcutaneous injection
Arm 2: Placebo Comparator, Placebo Subcutaneous injection
Participants with established cardiovascular disease (CVD)
Target
Patients
Readout
2027
Milestone(s)
Publication
TBD
Oncology
Appendix
Abbreviations
Other
65 Investor Relations | Q4 2022 Results
NOVARTIS | Reimagining MedicineView entire presentation